PALISADE BIO, INC. Tax Withholding Paid on Stock Awards
PALISADE BIO, INC. (PALI) reported Tax Withholding Paid on Stock Awards of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-03-20
- PALISADE BIO, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00.
- PALISADE BIO, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00.
- PALISADE BIO, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-12-31 was $0.00.
- PALISADE BIO, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-09-30 was $0.00.
- PALISADE BIO, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PALISADE BIO, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $25.00K.
- PALISADE BIO, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $0.00 derived: sum of 2 quarters · filed 2026-03-20 | $0.00 10-K · filed 2026-03-20 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $0.00 derived: sum of 2 quarters · filed 2026-03-20 | $25.00K 10-K · filed 2026-03-20 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $25.00K 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $25.00K 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 10-K · filed 2025-03-24 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |